Abbvie Inc
XETRA:4AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abbvie Inc
XETRA:4AB
|
US |
|
New York Community Bancorp Inc
NYSE:NYCB
|
US |
|
B
|
Brunswick Corp
SWB:BWI
|
US |
|
GAIL (India) Ltd
NSE:GAIL
|
IN |
|
Inaba Denki Sangyo Co Ltd
TSE:9934
|
JP |
|
Domtar Corp
TSX:UFS
|
US |
|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
SA |
|
C
|
Corporate Office Properties Trust
F:WX7
|
US |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Chemours Co
NYSE:CC
|
US |
|
G
|
Galderma Group AG
SIX:GALD
|
CH |
|
Huron Consulting Group Inc
NASDAQ:HURN
|
US |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
US |
|
V
|
VGI PCL
SET:VGI
|
TH |
|
Whitestone REIT
NYSE:WSR
|
US |
|
U
|
United Plantations Bhd
KLSE:UTDPLT
|
MY |
Wall St Price Targets
4AB Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for 4AB is 221.23 EUR with a low forecast of 163 EUR and a high forecast of 295.84 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 4AB's stock price target?
Price Target
221.23
EUR
According to Wall Street analysts, the average 1-year price target for 4AB is 221.23 EUR with a low forecast of 163 EUR and a high forecast of 295.84 EUR.
What is the Revenue forecast for Abbvie Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for Abbvie Inc?
Projected CAGR
11%
Over the last 14 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 8 years is 11%.
What is the Net Income forecast for Abbvie Inc?
Projected CAGR
32%
Over the last 14 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 8 years is 32%.
